As of 2025, the U.S. Food and Drug Administration (FDA) has authorized six autologous CAR-T products: four targeting CD19—Kymriah® (Tisagenlecleucel) [4] for r/r ALL, Yescarta® (Axicabtagene Ciloleucel) [5], Breyanzi® (Lisocabtagene Maraleucel) [6] for r/r diffuse large B cell lymphoma (DLBCL), Tecartus® (Brexucabtagene Autoleucel) [7] for r/r mantle cell lymphoma (MCL), alongside two B cell maturation antigen (BCMA)-directed therapies for multiple myeloma (MM), Abecma® (Idecabtagene Vicleucel) [8] and Carvykti® (Ciltacabtagene Autoleucel) [9] (Table 1). Here, TNFRSF17 is linked to acute lymphoblastic leukemia.